Search

everythinglearnresearchcommunity

for

Search:↓

The shed phase from using finasteride and minoxidil can vary, with some experiencing noticeable hair loss and others having minimal shedding. Despite initial shedding, many users report eventual hair regrowth and improvement, making the treatment worthwhile.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The user is experiencing a difficult shedding phase after starting a hair loss treatment with oral finasteride, topical minoxidil, and microneedling. Despite the shedding, they remain hopeful for regrowth and plan to continue the treatment, encouraged by others' positive results.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

The user is using finasteride and topical minoxidil for hair loss after previously trying them separately without success. They are experiencing a shedding phase but are committed to the treatment.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

A user who underwent a hair transplant in their twenties and are now discussing the best treatments for long-term management of hair loss, such as finasteride and Minoxidil, as well as potential alternative treatment options like RU58841.

The user experienced significant hair loss after extended fasting, initially thought to be Telogen Effluvium, but later suspected male pattern baldness. They tried finasteride briefly but stopped due to concerns about side effects, and are unsure if the hair loss is due to Telogen Effluvium or another cause.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

A user is questioning if they are experiencing hair regrowth after using minoxidil for nearly three months, along with saw palmetto, pumpkin seed oil, nizoral shampoo, and dermarolling. They are considering starting finasteride in February.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

A 20-year-old started using minoxidil, rosemary oil, Alpecin caffeine shampoos, scalp massager, derma rollers, and supplements for hair regrowth, seeing significant improvement initially. However, after 6 months, they noticed increased shedding and thinning, causing concern about whether this is normal or indicative of a problem.

The user started using 2.5 mg Minoxidil and 1.5 mg Finasteride five months ago, experienced initial shedding, saw progress, but is now concerned about recent hair loss. Another user reassures them that shedding is normal and suggests continuing the treatment.

Hair transplantation involves a detailed consultation, preparation, and a long-term recovery process with stages like initial shedding and gradual new hair growth over months. Setting realistic expectations is crucial for patient satisfaction.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Maintaining scalp hair and minimizing shedding, treatments used such as Procapil, supplements, topical caffeine, topical estrogen, and scalp massage; suggestions for anagen extenders or pharmaceuticals to help with a short anagen phase.

The conversation is about hair loss treatment progress using oral finasteride, topical minoxidil, and microneedling. Users discuss experiencing shedding phases and the importance of trusting the process for hair regrowth.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The user experienced hair regrowth and thickening using 1mg oral finasteride, 3mg oral minoxidil, biotin, vitamin D, red light therapy, and microneedling. Some shedding occurred around 4-6 weeks into the treatment.